New paediatric approval for Crestor
This article was originally published in Scrip
Executive Summary
The US FDA has approved AstraZeneca's hypolipaemic Crestor (rosuvastatin) for use in paediatric patients aged 10–17 years with heterozygous familial hypercholesterolaemia when diet alone has failed to reduce elevated cholesterol levels. AstraZeneca says it has no plans to actively promote this indication for Crestor, however.